NASDAQ · KA
Healthcare · Biotechnology
$0.57
Down-$0.26 (-30.77%)
Updated Aug 22, 2026, 8:39 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
KA does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning KA.
KA research
Company profile and research snapshot.
Kineta, Inc., a clinical stage biotechnology company, develops immunotherapies for oncology, neuroscience, and biodefense. It serves private, government, and industry partners. The company has strategic partnerships with Pfizer, Genentech, Wellcome, and Samsung Biologics Co., Ltd. Kineta, Inc. was formerly known as Lecura, Inc. The company was incorporated in 2007 and is based in Seattle, Washington.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jan 18, 2024 | HC Wainwright & Co. | Buy | — |
| Aug 21, 2023 | HC Wainwright & Co. | Buy | — |
| May 18, 2023 | HC Wainwright & Co. | Buy | — |
| May 1, 2023 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Sep 19, 2024
Kineta, a clinical-stage biotechnology company, has transitioned from Nasdaq to the OTC Market and is trading under the symbol 'KANT'. The company remains focused on advancing its KVA12123 Phase 1 clinical program and exploring strategic alternatives, including an exclusivity agreement with TuHURA Biosciences.
GlobeNewswire Inc. · Aug 19, 2024
Kineta has resumed enrollment for its VISTA-101 Phase 1/2 clinical trial evaluating KVA12123 in patients with advanced solid tumors. The trial had been suspended due to funding issues, but Kineta has now secured a $5 million payment from TuHURA Biosciences and is working with them to complete the trial enrollment by the end of 2024.
GlobeNewswire Inc. · May 15, 2024
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts
GlobeNewswire Inc. · Apr 8, 2024
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning KA.
No results
No recent SID articles mention KA.
